🎉 Welcome to OligoTune Limited, Robert Page! 🎉 We are thrilled to announce that Robert has joined OligoTune Limited as our first hire and Senior Scientist. Robert brings a wealth of experience and expertise in immuno-oncology, and we are excited to have him onboard as we continue to push innovation in the field of siRNA therapies to treat solid tumors. To get to know him better, we asked Robert a few questions about his new role and what excites him about joining OligoTune. Q: What made you excited to join OligoTune Limited? Robert: "What excited me most about joining OligoTune Limited was the opportunity to be part of a cutting-edge company that is at the forefront of developing truly novel immuno-oncology therapeutics. OligoTune’s commitment to innovation, combined with its collaborative culture, made it a perfect fit for me." Q: What are you looking forward to achieving in your new role? Robert: "In my new role at OligoTune, I’m looking forward to advancing the development of siRNA therapies that can make a meaningful difference for patients with solid tumors. I’m particularly excited to collaborate with the team to push forward innovative solutions, enhance the effectiveness of our treatments, and ultimately bring us closer to therapies that can improve patient outcomes." Q: What excites you most about the future of OligoTune? Robert: "What excites me most about the future of OligoTune is the immense potential we have to improve cancer treatment outcomes through our work developing siRNA technology for solid tumors. It’s an exciting time in general for both the fields of immuno-oncology and RNA-based therapeutics. OligoTune is uniquely positioned to lead the way in both with innovative and impactful solutions." Please join us in welcoming Robert to the OligoTune family! We are excited for the incredible work we’ll achieve together as we pioneer new treatments for solid tumors. #Welcome #NewHire #SeniorScientist #OligoTune #siRNA #oligonucleotides #CancerResearch #Innovation #SolidTumors #Teamwork
About us
OligoTune Ltd is dedicated to bringing new hope and improved outcomes to cancer patients through its pioneering RNA technology. Our mission is to create effective, patient-centred treatments that directly activate the body’s immune system within the tumour microenvironment. We are committed to providing innovative therapies that address the urgent needs of patients, especially those with therapy-resistant solid tumours. Our technology leverages small interfering RNA (siRNA) to reprogram the Tumour Immune Microenvironment (TIME), targeting key immunosuppressive factors. This approach allows us to address multiple resistance mechanisms simultaneously and target previously undruggable targets. Our solution is flexible, safe, and capable of multiplexing, offering precise and effective modulation of the immune system. OligoTune is actively developing drug candidates and collaborating with partners to advance our mission. With a strong commitment to research and development, we focus on delivering innovative and patient-centred cancer therapies. Through our groundbreaking work and partnerships, we aim to transform cancer treatment and bring new hope to patients around the world.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2024
Updates
-
Join us in Cardiff for this event! Looking forward to be discussing the future of RNA therapeutics!
CatSci Ltd are thrilled to invite you to our free in-person oligonucleotides event, entitled: “UK Innovation: The Future of RNA Therapeutics”🧬 This free oligos event will bring together renowned UK experts in the RNA field. Some of our expert speakers include: • Loïc Roux – CTO, OligoTune • Mike Webb PhD – Founder & CEO, Mike Webb Pharma • Nigel Richardson – Director of New Modalities, CatSci Ltd We will be announcing more speakers in due course, so be sure to keep an eye out for more exciting announcements. • When: 5th November 2024 • Where: CatSci Headquarters, Cardiff, CF3 2PW To register for this free event, sign up here: https://lnkd.in/essedN8a #Oligonucleotides #RNAtherapeutics #Oligos #UKoligos #OligosEvent #ScienceConference #ProudToBeCatSci #ExcellenceInMedicinesDevelopment
-
🚨 Exciting News! Oligotune is proud to announce that we have received support from Innovate UK under the #CancerTherapeutics program. This recognition underscores our commitment to innovation and excellence in finding new ways to fight cancer. A big thank you to our dedicated team and valued partners for their continued support. We’re excited to keep pushing boundaries and making a difference! #Innovation #Award #Oligotune #Excellence
📣🧬🔬💉 Innovate UK #CancerTherapeutics programme awards £12 million funding to advance 23 innovative cancer projects 💉🔬🧬📣 Industry-led R&D £11.3 million will be shared by 16 projects led by SMEs at various stages right from feasibility through to regulatory approval. 💉Momentous Therapeutics Ltd is developing drugs targeting a fundamental, ancient mechanism controlling immune activation, which will turbo-charge immune attack of tumours. 🧬Revolver Therapeutics is identifying tiny proteins, known as peptides, that can enter cells to shut down DNA-binding proteins strongly associated with high-grade childhood brain and spinal tumours. Feasibility studies Seven organisations will receive a share of £700,000 to complete feasibility studies to develop new approaches in cancer therapeutics. 🔬 One of the successful companies is OligoTune which will use its grant to enhance its immune system activating RNA technology to develop potent cancer therapies, aiming to improve the treatment of solid tumours. 💊 Another, Galytx is developing novel and potentially transformative therapeutic drugs for the most aggressive cancers. Their project will help them to accelerate their development strategy. The Cancer Therapeutics programme focuses on developing life-changing cancer treatments, including immunotherapies and vaccines. It also supports projects addressing medical needs for treating childhood and young persons’ cancers. Read the full article here: https://ow.ly/KoP350T8GTv #Feasibility #R&D #PaediatricOncology #CancerImmunotherapy #CancerResearch #CancerVaccine #ImmunoOncology
£12 million funding awarded to advance innovative cancer projects
ukri.org
-
OligoTune reposted this
🚀 Fresh off the wire: Introducing OligoTune, a new startup dedicated to tackling a major challenge in clinical oncology: the resistance in solid tumours. We're thrilled to collaborate with Deep Science Ventures and Loïc Roux to advance #OligoTune ’s cutting-edge bioinformatics and multiplex #RNA technology, aiming for enhanced outcomes for #immunotherapy patients. Find out more: https://lnkd.in/dPzVW6wt Hamish Ryder, Beatrice Lana, Laura Fletcher, PhD, Dominic Falcão, Tanya Moore, Julie Little, RTTP, CSAP #OnMyHorizon #PortfolioNews
-
We're thrilled to announce the official launch of OligoTune, a groundbreaking approach to cancer treatment using advanced RNA technology. Together with our esteemed partners, Cancer Research Horizons and Deep Science Ventures, we aim to redefine therapy for solid tumours by transforming the landscape of cancer treatment. Through our groundbreaking work and partnerships, our novel RNA-based technology set to target therapy-resistant solid tumours aims to bring new hope to patients around the world. Follow our journey OligoTune as we write a new chapter in cancer therapy. #OligoTune #CancerResearchHorizon #DeepScienceVentures #CancerTherapy #RNAtechnology #InnovativeMedicine #HealthcareInnovation #Biotech#InnovateOncology #CancerCare